# Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics

> **NCT04126538** · PHASE1 · UNKNOWN · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** pirfenidone capsule
- **DRUG:** pirfenidone capsule

## Key facts

- **NCT ID:** NCT04126538
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-27
- **Primary completion:** 2021-11-25
- **Final completion:** 2022-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126538, "Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04126538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*